Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1612 1638
This examiner grants 77% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18009476 | BACULOVIRUS EXPRESSION SYSTEMS | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 18246279 | VACCINE COMPOSITIONS FOR MUCOSAL IMMUNE RESPONSE | Non-Final OA | NANTCELL INC. |
| 18569550 | PRIMORDIAL GERM CELLS | Non-Final OA | The Regents of the University of California |
| 18354719 | METHOD FOR PRODUCING FOOD PRODUCTS USING CELLS GROWN IN CULTURE AS AN ALTERNATIVE TO ANIMAL HUSBANDRY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18074402 | ENGINEERED VASCULARIZED ORGANOIDS | Non-Final OA | The Regents of the University of California |
| 17995114 | Kidney Organoids Having a Nephron-like Structure and Methods of Preparing the Same | Non-Final OA | POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION |
| 17770463 | PATIENT-MATCHED ORGANOID SYSTEMS FOR STUDYING CANCER | Non-Final OA | Massachusetts Institute of Technology |
| 18040971 | RECOMBINANT ADENO-ASSOCIATED VIRUS FOR TREATMENT OF GRN-ASSOCIATED ADULT-ONSET NEURODEGENERATION | Final Rejection | The Trustees of the University of Pennsylvania |
| 18855043 | piRNA-BASED CONSTRUCTS FOR REGULATING GENE EXPRESSION AND METHODS OF USE THEREOF | Non-Final OA | Rutgers, The State University of New Jersey |
| 17439733 | METHODS AND MATERIALS FOR TREATING CANCER | Final Rejection | The Penn State Research Foundation |
| 17779639 | Composition for Medium | Final Rejection | Kyoto Prefectural Public University Corporation |
| 18556827 | METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | Non-Final OA | MESOBLAST INTERNATIONAL SÁRL |
| 18556845 | METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | Non-Final OA | MESOBLAST INTERNATIONAL SÁRL |
| 18066999 | METHOD FOR STABLY AMPLIFYING PLURIPOTENT STEM CELL | Non-Final OA | Gwo Xi Stem Cell Applied Technology Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy